Back to Journals » Therapeutics and Clinical Risk Management » Volume 5

Role of oxaliplatin in the treatment of colorectal cancer

Authors Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L

Published 4 March 2009 Volume 2009:5 Pages 229—238


Review by Single-blind

Peer reviewer comments 2

Pasquale Comella, Rossana Casaretti, Claudia Sandomenico, Antonio Avallone, Luca Franco

Unit of Medical Oncology, Department of Gastrointestinal Tract Cancers, National Tumor Institute, Naples, Italy

Abstract: Oxaliplatin is a third-generation platinum compound that has shown a definite role in the management of colorectal cancer (CRC). Oxaliplatin in combination with fluorouracil and leucovorin in the FOLFOX4 regimen represents a new standard of treatment in the adjuvant setting as well as for the metastatic disease. The combination of oxaliplatin with capecitabine in the XELOX regimen has been demonstrated to be not inferior to FOLFOX4 in metastatic patients, and it is under evaluation, with or without bevacizumab, in the post-surgical management of resected patients. FOLFOX4 and XELOX regimens represent a backbone on which to add new targeted drugs. Indeed, the combination of bevacizumab with either FOLFOX4 or XELOX significantly prolonged the progression-free survival and overall survival in comparison with FOLFOX4 or XELOX combined with placebo in metastatic CRC patients, while FOLFOX4 plus cetuximab produced a significantly greater activity than FOLFOX4 alone in metastatic CRC patients with K-RAS wild type.

Keywords: oxaliplatin, fluorouracil, leucovorin, colorectal cancer, advanced disease, adjuvant treatment, cetuximab, bevacizumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]